Alnylam Pharmaceuticals (ALNY) EBITDA Margin (2009 - 2026)
Alnylam Pharmaceuticals' (ALNY) quarterly EBITDA Margin came in at 17.93% in Q2 2026, up 2002.0% on a YoY basis from 0.85% in Q2 2025, and down 22.11% quarter-over-quarter from 23.02% in Q1 2026.
Powered by 
Analysis
Alnylam Pharmaceuticals (ALNY) EBITDA Margin (2009 - 2026) Analysis & Trends
Alnylam Pharmaceuticals (ALNY) has reported EBITDA Margin for 18 consecutive years, with 17.93% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, EBITDA Margin rose 2002.0% year-over-year to 17.93%; the trailing twelve-month figure through Jun 2026 stood at 20.81% (up 3031.0% YoY), and the FY2025 full-year result was 13.51%, up 2137.0% from the prior year.
- EBITDA Margin eased to 17.93% in Q2 2026 per ALNY's latest filing, from 23.02% in the prior quarter.
- Across five years, EBITDA Margin topped out at 60.26% in Q1 2025 and bottomed at 97.63% in Q3 2022.
- Historically, EBITDA Margin has averaged 17.72% across 5 years, with a median of 12.07% in 2024.
- The sharpest annual moves came in 2023 and 2024: EBITDA Margin surged 12612 bps in 2023, then slumped 4385 bps in 2024.
- Over 5 years, EBITDA Margin stood at 56.3% in 2022, then jumped by 53 bps to 26.47% in 2023, then jumped by 33 bps to 17.73% in 2024, then surged by 168 bps to 12.01% in 2025, then jumped by 49 bps to 17.93% in 2026.
- According to Business Quant data, EBITDA Margin over the past three periods registered 17.93%, 23.02%, and 12.01% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 34.95% |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | -133.21% |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 37.40% |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 30.15% |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 32.54% |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | -562.07% |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 17.93% |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | -23.56% |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | -0.36% |
| 10 | BioNTech SE | 26.24 Bn | 12.58 Bn | 10.00 Mn | -897.82% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 17.93% |
| Mar 31, 2026 | 23.02% |
| Dec 31, 2025 | 12.01% |
| Sep 30, 2025 | 29.46% |
| Jun 30, 2025 | -2.09% |
| Mar 31, 2025 | 60.26% |
| Dec 31, 2024 | -17.73% |
| Sep 30, 2024 | -15.35% |
| Jun 30, 2024 | 7.37% |
| Mar 31, 2024 | -8.79% |
| Dec 31, 2023 | -26.47% |
| Sep 30, 2023 | 28.50% |
| Jun 30, 2023 | -72.10% |
| Mar 31, 2023 | -46.92% |
| Dec 31, 2022 | -56.30% |
| Sep 30, 2022 | -97.63% |
| Jun 30, 2022 | -85.26% |
| Mar 31, 2022 | -68.80% |
| Dec 31, 2021 | -75.26% |
| Sep 30, 2021 | -96.83% |